Proteome Sciences plc (LON:PRM) has received notification from Vulpes Life Sciences Fund (“Vulpes”) that on 02 May 2017 it purchased 100,000 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,143,715 equivalent to 18.38% of Proteome Sciences’ total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,143,715 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.
Proteome Sciences plc is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia. The company has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer’s disease, and these are available for license.
